Sign In
Buy GOVX
$1.32
-0.0200 (-1.49%)
At Close: Jun 22, 2026
ATLANTA, GA, April 30, 2020 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious.
GeoVax Applauds and Comments on Passage of $2 Trillion CARES Act
01:00pm, Monday, 30'th Mar 2020
ATLANTA, GA, March 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --GeoVax Labs, Inc. (GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ca
GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update
01:00pm, Wednesday, 25'th Mar 2020
ATLANTA, GA, March 25, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and ca
GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program
01:00pm, Wednesday, 18'th Mar 2020
ATLANTA, GA, March 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and c
GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program
06:00pm, Wednesday, 04'th Mar 2020
ATLANTA, GA, March 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and ca
Maharashtra govt to give 5% quota to backward Muslim students
08:23am, Saturday, 29'th Feb 2020
Maharashtra's MVA government plans to bring in a law to provide five percent reservations to backward Muslims in government education institutions.
GeoVax to Present at World Immunotherapy Congress 2020
02:00pm, Thursday, 27'th Feb 2020
ATLANTA, GA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and can
Update: GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
04:50pm, Thursday, 06'th Feb 2020
ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX) (GOVXD), a biotechnology company developing human immunotherapies and vaccines against infectious diseas
GeoVax Prepared to Advance GOVX-B11 HIV Vaccine to Next Clinical Trial
02:00pm, Thursday, 06'th Feb 2020
ATLANTA, GA, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and c
GeoVax and BravoVax (Wuhan, China) to Collaborate on Development of Coronavirus Vaccine
03:18pm, Monday, 27'th Jan 2020
ATLANTA, GA, and WUHAN, CHINA, Jan. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (GOVXD), a biotechnology company developing human immunotherapies and vaccines against infecti
GeoVax Announces Reverse Stock Split
02:00pm, Thursday, 23'rd Jan 2020
1:2000 Reverse Split Effective January 24, 2020;Ticker Symbol Changed to GOVXD for 20 Days ATLANTA, GA, Jan. 23, 2020 -- via NEWMEDIAWIRE – GeoVax Labs, Inc. (OTC: GOVX).
GeoVax to Present at World Vaccine & Immunotherapy Conference
02:00pm, Tuesday, 03'rd Dec 2019
Two Separate Presentations to Focus on the Company’s Infectious Disease Vaccines and Cancer Immunotherapy Programs ATLANTA, GA, Dec. 03, 2019 -- via NEWMEDIAWIRE -- GeoVax.
GeoVax Observes 2019 World AIDS Day
02:00pm, Monday, 02'nd Dec 2019
Developing Multiple Strategies Toward Ending the HIV/AIDS Epidemic ATLANTA, GA, Dec. 02, 2019 -- via NEWMEDIAWIRE -- GeoVax Labs, Inc. (OTC: GOVX), a biotechnology.
GeoVax to Present at Vaccines R&D Conference
02:00pm, Thursday, 14'th Nov 2019
Presentation to Focus on the Company’s MVA-VLP Platform for Safe and Effective Vaccines for Infectious Diseases and Cancer ATLANTA, GA, Nov. 14, 2019 -- via NEWMEDIAWIRE --.
GeoVax Vaccine Selected to Participate in Development of Potential HIV Functional Cure
02:00pm, Wednesday, 13'th Nov 2019
The proposed clinical trial will enroll 20 HIV-infected adults who are on stable and effective antiretroviral therapy (ART). The therapeutic regimen to be tested involves a combination of vaccination
